home / stock / rcus / rcus quote
Last: | $14.65 |
---|---|
Change Percent: | -0.13% |
Open: | $15.32 |
Close: | $14.65 |
High: | $15.34 |
Low: | $14.25 |
Volume: | 725,691 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$14.65 | $15.32 | $14.65 | $15.34 | $14.25 | 725,691 | 07-02-2024 |
$15.3 | $15.19 | $15.3 | $15.47 | $14.97 | 410,812 | 07-01-2024 |
$15.23 | $15.32 | $15.23 | $15.42 | $14.75 | 2,219,809 | 06-28-2024 |
$15.17 | $15.16 | $15.17 | $15.34 | $14.75 | 651,759 | 06-27-2024 |
$15.16 | $15.7 | $15.16 | $15.87 | $15.16 | 586,528 | 06-26-2024 |
$15.83 | $16.32 | $15.83 | $16.42 | $15.53 | 921,978 | 06-25-2024 |
$16.41 | $16.5 | $16.41 | $16.78 | $16.17 | 541,663 | 06-24-2024 |
$16.35 | $16.42 | $16.35 | $16.815 | $16.01 | 3,745,365 | 06-21-2024 |
$16.19 | $15.78 | $16.19 | $16.36 | $15.47 | 718,527 | 06-20-2024 |
$15.99 | $16.2 | $15.99 | $16.2 | $15.35 | 980,892 | 06-19-2024 |
$15.99 | $16.2 | $15.99 | $16.2 | $15.35 | 980,892 | 06-18-2024 |
$16.2 | $16.87 | $16.2 | $16.9 | $16.03 | 1,119,218 | 06-17-2024 |
$16.97 | $16.86 | $16.97 | $17.18 | $16.43 | 1,430,771 | 06-14-2024 |
$17 | $15.78 | $17 | $17.08 | $15.65 | 938,523 | 06-13-2024 |
$15.81 | $16.25 | $15.81 | $16.49 | $15.61 | 789,558 | 06-12-2024 |
$15.65 | $15.88 | $15.65 | $16.01 | $15.405 | 532,989 | 06-11-2024 |
$16.09 | $15.27 | $16.09 | $16.11 | $15.115 | 659,823 | 06-10-2024 |
$15.5 | $15.75 | $15.5 | $16.055 | $15.47 | 514,114 | 06-07-2024 |
$15.9 | $16.27 | $15.9 | $16.31 | $15.77 | 467,466 | 06-06-2024 |
$16.28 | $16.07 | $16.28 | $16.34 | $15.8 | 638,775 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 45 th Annual ...
2024-06-04 14:00:07 ET Peter Lawson from Barclays issued a price target of $35.00 for RCUS on 2024-06-04 09:49:00. The adjusted price target was set to $35.00. At the time of the announcement, RCUS was trading at $16.15. The overall price target consensus is at $42.00 wi...